Abstract: The invention provides a double-stranded ribonucleic acid (dsRNA) having a chain length suitable for simultaneously showing low toxicity and high function in the use of an adjuvant and the like, and resisting variation of chain length even when subjected to a heating and cooling treatment, or a salt thereof; an immune potentiator, adjuvant, pharmaceutical product and the like containing the dsRNA and the like; and a production method of such dsRNA and the like. The invention is characterized in that the weight average chain length of two or more single-stranded ribonucleic acids (ssRNAs) constituting the first chain constituting dsRNA is not more than ½ of the weight average chain length of one ssRNA constituting the second chain.
Abstract: The present invention relates to a method for purifying a non-spreading botulinum toxin that causes local muscle paralysis and a non-spreading botulinum toxin obtained thereby. The method comprises the steps of: subjecting a purified botulinum toxin type A product to ion-exchange chromatography using a controlled pH of buffer, concentration of sodium chloride (NaCl), thereby separating the botulinum toxin type A product into subfractions; and collecting a subfraction having an A260/A280 value in a specific range from the separated subfractions.
Abstract: Immunogenic compositions containing Escherichia coli 0157:H7 flagella including fusion proteins and methods using the immunogenic compositions are disclosed. Inducing an immune response in an animal to Escherichia coli O157:H7 flagella will result in prevention of colonization by Escherichia coli O157:H7 in the animal or a reduction in the amount of Escherichia coli O157:H7 infecting the animal. The immune composition will prevent or reduce the attachment of Escherichia coli 0157:H7 to cells within the animal.
Type:
Grant
Filed:
November 23, 2015
Date of Patent:
July 30, 2019
Assignees:
The University Court of the University of Edinburgh, Moredun Research Institute, SRUC
Inventors:
David Gally, Tom Nathan McNeilly, David George Emslie Smith, Chris Low, Arvind Kumar Mahajan, Stuart W. Naylor
Abstract: Methods of diagnosing and treating patients afflicted with acne, including diagnosing one as having acne if the individual possesses RT4, RT5, RT7, RT8, RT9, or RT10. Methods for treating acne include administering an effective amount of a drug specifically targeting RT4, RT5, RT7, RT8, RT9, or RT10, such as small molecules, antisense molecules, siRNAs, biologics, antibodies, phages, vaccines, or combination thereof.
Type:
Grant
Filed:
September 6, 2016
Date of Patent:
July 30, 2019
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Huiying Li, Shuta Tomida, Robert L. Modlin, Jeffery F. Miller, Sorel T. Fitz-Gibbon
Abstract: The present invention relates generally to immunogenic combinations comprising at least five antigens of a Mycobacterium species as well as fusion thereof and nucleic acid molecules encoding such combined antigens and fusion. The present invention also relates to nucleic acid molecules, vectors, host cells and compositions comprising or encoding said combinations of mycobacterial antigens and fusion polypeptides as well as to methods for recombinantly producing them. The present invention also relates to methods of using said combinations of mycobacterial antigens, fusion polypeptides, vectors, host cells, compositions particularly for inducing or stimulating an immune response against a Mycobacterium infection or any disease caused by or associated with a Mycobacterium infection.
Type:
Grant
Filed:
July 10, 2013
Date of Patent:
July 23, 2019
Assignee:
TRANSGENE SA
Inventors:
Emmanuel Tupin, Romain Micol, Charles Antoine Coupet, Geneviève Inchaupse, Marie Gouanvic, Nathalie Silvestre, Jean-Baptiste Marchand, Cécile Beny
Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
Type:
Grant
Filed:
October 15, 2018
Date of Patent:
July 9, 2019
Assignees:
The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
Inventors:
Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
Abstract: The present invention relates to a medium composition for production of botulinum toxin and, more particularly, to a medium composition for culture of Clostridium sp. capable of producing botulinum toxin. The medium composition of the present invention comprises a porcine peptone and at least one plant-derived peptone selected from the group consisting of a garden pea hydrolysate, a cotton seed hydrolysate and a wheat gluten hydrolysate. When the medium according to the present invention, which contains plant-derived peptones, porcine peptones and minerals, is used for culture of Clostridium botulinum, the growth rate of the bacterium in the medium is higher than that in each of the medium that is in current use and the medium comprising plant-derived peptones alone. In addition, when the medium of the present invention is used, a high concentration of botulinum toxin can be produced by culturing the bacterium in a safe manner.
Type:
Grant
Filed:
April 28, 2016
Date of Patent:
June 4, 2019
Assignee:
DAEWOONG CO., LTD.
Inventors:
Kyoung-Yun Kim, Hye-Young Sul, Kyoung-Min Min
Abstract: This disclosure provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
Type:
Grant
Filed:
August 16, 2016
Date of Patent:
June 4, 2019
Assignee:
The Regents of the University of California
Abstract: The present invention relates to: a novel cell penetrating peptide; a cell penetrating botulinum toxin recombinant protein composition in which the cell penetrating peptide and the light chain of a botulinum toxin are fused; and a use thereof and, more specifically, to a composition enabling the transdermal delivery of a cell penetrating botulinum toxin recombinant protein and capable of being locally used for various treatments of the skin and cosmetic purposes. The cell penetrating peptide-botulinum toxin recombinant protein of the present invention can be transdermally delivered, thereby having the intrinsic effect of a botulinum toxin and simultaneously having greater convenience of use, and thus can be effectively applied as a local agonist for the treatment of various diseases and aesthetic and/or cosmetic purposes.
Type:
Grant
Filed:
May 29, 2015
Date of Patent:
May 28, 2019
Assignee:
PROCELL THEREPAUTICS INC.
Inventors:
Byung Kyu Lee, Kang Jin Lee, MinJoong Kim, HongGyu Park
Abstract: The present invention relates to methods for constructing a filamentous fungal strain for production of multiple recombinant polypeptides having biological activity. The present invention also relates to methods for producing multiple recombinant polypeptides having biological activity in a filamentous fungal strain. The present invention also relates to filamentous fungal strains expressing multiple recombinant polypeptides having biological activity.
Abstract: Disclosed herein is a liquid pharmaceutical composition of botulinum toxin which is improved in stability. It comprises botulinum toxin, polysorbate 20, and methionine and optionally isoleucine. Employing, instead of the animal-derived protein albumin or gelatin, a combination of polysorbate 20 and methionine and optionally isoleucine as botulinum toxin stabilizers, the liquid pharmaceutical composition eliminates the risk of contaminating the body with serum-derived pathogens or microorganisms and can be administered safely to the body. Also, the composition is convenient for use as a direct injection for patients. Superior to conventional compositions employing either detergents or amino acids in terms of the storage stability of botulinum toxin at 25˜37° C. as well as at refrigerated temperatures, the liquid pharmaceutical composition of the present invention is very useful for storing botulinum toxin under an emergency condition such as an environment without maintaining low temperature.
Type:
Grant
Filed:
December 28, 2015
Date of Patent:
May 21, 2019
Assignee:
Medy-Tox, Inc.
Inventors:
Hyun Ho Jung, Gi Hyeok Yang, Hack Woo Kim, Hee Dong Woo, Chang Hoon Rhee
Abstract: The present invention is directed to pharmaceutical compositions and methods of inhibiting or blocking one or more virulence antigenic factors of Bacillus anthracis. Specifically, it involves the administering of an expression vector alone or in conjunction with a fusion protein. The expression vector has a transcription unit encoding a fusion protein composed of an antigenic factor of Bacillus anthracis attached through a linker to the aminoterminal end of the CD40 ligand. This fusion protein has the ability to generate antibodies which prevents Bacillus anthracis infection in an individual.
Abstract: Vaccines and compositions containing an attenuated L. monocytogenes prsA2 htrA deletion mutant for use in the presentation of foreign or exogenous antigens and in the treatment or prevention of diseases such as cancer or infectious disease are provided.
Type:
Grant
Filed:
April 7, 2015
Date of Patent:
May 21, 2019
Assignees:
The Board of Trustees of the University of Illinois, Montana State University
Abstract: The invention relates to nucleic acid modifications for a directed expression modulation by the targeted insertion or removal of CpG dinucleotides. The invention also relates to modified nucleic acids and expression vectors.
Type:
Grant
Filed:
September 10, 2014
Date of Patent:
April 30, 2019
Assignee:
GENEART AG
Inventors:
Frank Notka, Marcus Graf, Doris Baumann, Ralf Wagner, David Raab
Abstract: The present invention relates to a Myoviridae bacteriophage Esc-CHP-2 that is isolated from the nature and can kill specifically enteropathogenic E. coli strains, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12661BP), and a method for preventing and treating the infections of enteropathogenic E. coli using the composition comprising said bacteriophage as an active ingredient.
Type:
Grant
Filed:
December 28, 2015
Date of Patent:
April 23, 2019
Assignee:
INTRON BIOTECHNOLOGY, INC.
Inventors:
Seong Jun Yoon, Sang Hyeon Kang, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Byung Kuk Kim, Hee Jeong Shin
Abstract: The present invention relates to a Myoviridae bacteriophage Esc-COP-4 that is isolated from the nature and can kill specifically enteroinvasive E. coli strains, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12663BP), and a method for preventing and treating the infections of enteroinvasive E. coli using the composition comprising said bacteriophage as an active ingredient.
Type:
Grant
Filed:
December 28, 2015
Date of Patent:
April 23, 2019
Assignee:
INTRON BIOTECHNOLOGY, INC.
Inventors:
Seong Jun Yoon, Sang Hyeon Kang, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Byung Kuk Kim, Hee Jeong Shin, Dong Min Kang
Abstract: The present invention relates to a Myoviridae bacteriophage Esc-COP-1 that is isolated from the nature and can kill specifically Shigatoxin-producing type F18 E. coli strains, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12662BP), and a method for preventing and treating the infections of Shigatoxin-producing type F18 E. coli using the composition comprising said bacteriophage as an active ingredient.
Type:
Grant
Filed:
December 28, 2015
Date of Patent:
April 23, 2019
Assignee:
INTRON BIOTECHNOLOGY, INC.
Inventors:
Seong Jun Yoon, Sang Hyeon Kang, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Suk Hwang Park, Byung Kuk Kim
Abstract: The present invention relates to a Myoviridae bacteriophage Esc-CHP-1 that is isolated from the nature and can kill specifically enterohemorrhagic E. coli strains, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12660BP), and a method for preventing and treating the infections of enterohemorrhagic E. coli using the composition comprising said bacteriophage as an active ingredient.
Type:
Grant
Filed:
December 28, 2015
Date of Patent:
April 23, 2019
Assignee:
INTRON BIOTECHNOLOGY, INC.
Inventors:
Seong Jun Yoon, Sang Hyeon Kang, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Byung Kuk Kim, Hee Jeong Shin
Abstract: Compositions and methods for determining immunologically cross-reactive molecules comprising a cross-reactive antigenic determinant are provided, in particular for determining proteins comprising cross-reactive antigenic determinants, in particular for determining proteins that are cross-reactive based on serological screens using sequential immunological challenges to an animal, including determining cross-reactive H. parasuis proteins. Also provided are compositions, vaccines, and kits using the molecules for diagnostics and methods for preventing or treating a disease, disorder, condition, or symptoms thereof associated with infectious agents, in particular infectious microorganisms, in particular for preventing or treating a disease, disorder, condition, or symptom thereof associated with H. parasuis infection.
Type:
Grant
Filed:
April 27, 2015
Date of Patent:
April 16, 2019
Assignee:
Elanco Tiergesundheit AG
Inventors:
Thomas Plocher, Manuel Campos, Richard Harland, Todd Johnson, Trent Harbison, Dan Keil
Abstract: The invention provides methods of modulating an immune system in a vertebrate host for the therapeutic or prophylactic treatment of infection by a first microbial pathogen in a target tissue, comprising administration at an administration site of an effective amount of an antigenic formulation comprising antigenic determinants specific for a second heterologous microbial pathogen.
Type:
Grant
Filed:
May 1, 2015
Date of Patent:
April 9, 2019
Assignee:
Qu Biologics Inc.
Inventors:
Harold David Gunn, Salim Dhanji, David W. Mullins